Stockscreener 앱 받기
15.55
0.06%
0.01
Polyrizon Ltd 주식(PLRZ)의 최신 뉴스
Polyrizon recives Nasdaq delisting notice - MSN
Polyrizon explores investments in defense, aviation and AI sectors By Investing.com - Investing.com Nigeria
Polyrizon Ltd to explore revenue-generating investment opportunities in high-growth sectors - marketscreener.com
Polyrizon to Explore Revenue-Generating Investment Opportunities in High-Growth Sectors, Leveraging Strong Cash Position and Debt-Free Balance Sheet - The Manila Times
User - FinancialContent
Polyrizon (PLRZ) Stock Explodes on Naloxone Hydrogel Breakthrough and PL‑14 Upscaling – What Investors Should Know Now - TechStock²
Polyrizon Ltd. (PLRZ) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Can Polyrizon Ltd. stock rebound after recent weaknessPortfolio Gains Report & Technical Pattern Recognition Alerts - Улправда
PLRZ - Finviz
Is Polyrizon Ltd. stock undervalued vs historical averagesNew Releases Roundup & what to check before ordering - Улправда
Polyrizon names allergy blocker product NASARIX By Investing.com - Investing.com Australia
Why Polyrizon Ltd. stock is favored by top institutions2025 Winners & Losers & Fast Moving Trade Plans - Улправда
Polyrizon expects Nasarix introduction aligned with clinical progress - marketscreener.com
Polyrizon names allergy blocker product NASARIX - Investing.com
Polyrizon Brands PL-14 Intranasal Allergy Blocker as NASARIX™ - TipRanks
Polyrizon Completes Branding Process for PL-14 Allergy Blocker with Brand Name NASARIX™ - The Manila Times
Polyrizon Completes Branding Process for PL-14 Allergy Blocker with Brand Name NASARIX - Bluefield Daily Telegraph
NASARIX: a new nasal spray brand designed to shield against allergens - Stock Titan
Polyrizon’s PL-14 shows strong pre-clinical allergen-blocking advantage over standard nasal barrier - MSN
Polyrizon announces in-vitro results for PL-16 Viral Blocker - MSN
Polyrizon stock rises after positive pre-clinical allergy blocker results By Investing.com - Investing.com Nigeria
Polyrizon stock rises after positive pre-clinical allergy blocker results - Investing.com
Polyrizon Announces Positive Data From PL-14 Allergy Blocker Formulation Study - Nasdaq
Polyrizon’s nasal allergy blocker outperforms standard in lab study By Investing.com - Investing.com South Africa
Polyrizon’s PL-14 Shows Strong Pre-Clinical Allergen-Blocking Advantage Over Standard Nasal Barrier - TipRanks
Polyrizon’s nasal allergy blocker outperforms standard in lab study - Investing.com India
Polyrizon Announces New Pre-Clinical Results: PL-14 Demonstrates Significant Allergen-Blocking Performance Compared to a Standard Comparator - The Manila Times
About Us - FinancialContent
Polyrizon submits pre-request to FDA for nasal spray against flu - Investing.com Nigeria
Polyrizon submits pre-request to FDA for nasal spray against flu By Investing.com - Investing.com South Africa
Polyrizon stock rises on FDA submission for PL-16 viral blocker - Investing.com Australia
As Flu Surge Continues, Polyrizon's Nasal Spray Emerges as Potential Extra Shield Solution for Both Vaccinated and Unvaccinated - The Manila Times
Polyrizon (PLRZ) Stock Analysis Report | Financials & Insights - Benzinga
Polyrizon reports mucoadhesion results for intranasal naloxone hydrogel - MSN
Polyrizon Ltd. to Explore Investment Opportunities in Revenue-Generating Real Assets - marketscreener.com
Polyrizon to explore investments in revenue-generating assets By Investing.com - Investing.com Nigeria
Polyrizon to pursue revenue-generating real assets while advancing intranasal biotech pipeline - MSN
Polyrizon stock rises as company explores revenue-generating investments By Investing.com - Investing.com Nigeria
symbol__ Stock Quote Price and Forecast - CNN
4.73%
0.92%
자본화:
|
볼륨(24시간):